UNSPSC 51351514: Progesterone

This classification denotes a progestagen with the molecular formula C21H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G7DS2Q64Y, chemically known as 10.alpha.-pregn-4-ene-3,20-dione but generally known as progesterone, which bears US NIH Compound Identifier 4920. European Medicines Agency schedules Progesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10076MIG.

UNSPSC 51351514 Progesterone, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing agreements, with recent activity focused on establishing multi-source generic pharmaceutical and over-the-counter (OTC) product contracts across participating jurisdictions. State and local governments procure progesterone and related pharmaceutical commodities primarily through cooperative purchasing vehicles rather than direct agency solicitations, leveraging negotiated pricing and established wholesaler networks to supply healthcare facilities, clinics, and public health programs. The issuing bodies are typically state procurement offices administering multistate cooperative purchasing alliances that serve state agencies, counties, cities, school districts, and other local entities across multiple participating states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and contracts effective July 1, 2026. Evaluation prioritizes price competitiveness (75 percent) along with fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three authorized wholesalers, and carry comprehensive insurance including $5 million commercial general liability. The two-year contract term applies to new vendors with optional extensions at MMCAP's discretion. Activity centers on the upper Midwest with participation extending to Oregon, though the source does not identify other recent progesterone-specific solicitations or geographic concentrations beyond this multistate cooperative vehicle.